6.97
+0.17(+2.50%)
Currency In USD
Address
259 Liberty Avenue
Staten Island, NY 10305
United States of America
Phone
917-533-1469
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 25, 2021
| Name | Title | Pay | Year Born |
| Mr. David P. Luci CPA, Esq., J.D. | Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director | 786,883 | 1967 |
| Mr. Robert G. Shawah CPA | Co-Founder & Chief Financial Officer | 533,653 | 1967 |
| Mr. Robert J. DeLuccia | Co-Founder & Executive Chairman | 818,930 | 1946 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.